Literature DB >> 3891883

Immunopathologic mechanisms in pemphigus and bullous pemphigoid.

R E Jordon, S Kawana, K A Fritz.   

Abstract

Pemphigus and bullous pemphigoid are autoimmune bullous diseases of the skin. Pemphigus, an intraepidermal blistering disease, is characterized by autoantibodies reactive with antigens located in the intercellular spaces or on the surfaces of epidermal cells. These antibodies, which have recently been shown to activate complement, appear to be the cause of the basic pathologic process of pemphigus, acantholysis. The complement system and the plasminogen-plasmin system may be important mediators in the detachment of epidermal cells. Bullous pemphigoid, a subepidermal blistering disease, is characterized by autoantibodies reactive with an antigen located in the lamina lucida region of the basement membrane zone. These autoantibodies, which will avidly fix complement, appear to mediate subepidermal separation by attraction of a variety of inflammatory cells. Anaphylatoxins, released by activation of C4 and C3, or specific IgE antibodies, may activate mast cells with release of ECF-A attracting eosinophils. With activation of C5, C5a is released which could attract polymorphonuclear leukocytes. Antigen-specific lymphocytes, which can also contribute histamine releasing substances, may also be involved. The exact mechanism by which the epidermis separates from the dermis in bullous pemphigoid, however, remains unresolved.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3891883     DOI: 10.1111/1523-1747.ep12275497

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  22 in total

Review 1.  Bullous pemphigoid: from bench to bedside.

Authors:  Scott R A Walsh; David Hogg; P Régine Mydlarski
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  The distribution of IgG subclass autoantibodies in bullous pemphigoid analysed by immunofluorescence and immunoblotting.

Authors:  H Soh; H Hosokawa; H Miyauchi; H Izumi; Y Asada
Journal:  Arch Dermatol Res       Date:  1991       Impact factor: 3.017

3.  1-2B7B: monoclonal antibody reacting to the 120 kDa polypeptide component of human epidermal hemidesmosomes.

Authors:  X M Zhang; Y Horiguchi; M Ueda; T Yoshiki; S Imamura
Journal:  Arch Dermatol Res       Date:  1991       Impact factor: 3.017

Review 4.  Complement and cutaneous autoimmune blistering diseases.

Authors:  Elizabeth Lessey; Ning Li; Luis Diaz; Zhi Liu
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

5.  Tryptase concentration in skin blister fluid from patients with bullous skin conditions.

Authors:  K Brockow; D Abeck; K Hermann; J Ring
Journal:  Arch Dermatol Res       Date:  1996-11       Impact factor: 3.017

6.  Demonstration of intra- and extracellular localization of bullous pemphigoid antigen using cryofixation and freeze substitution for postembedding immunoelectron microscopy.

Authors:  H Shimizu; J N McDonald; A R Kennedy; R A Eady
Journal:  Arch Dermatol Res       Date:  1989       Impact factor: 3.017

7.  A critical role for neutrophil elastase in experimental bullous pemphigoid.

Authors:  Z Liu; S D Shapiro; X Zhou; S S Twining; R M Senior; G J Giudice; J A Fairley; L A Diaz
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

8.  Tumor necrosis factor-alpha-induced proteolytic activation of pro-matrix metalloproteinase-9 by human skin is controlled by down-regulating tissue inhibitor of metalloproteinase-1 and mediated by tissue-associated chymotrypsin-like proteinase.

Authors:  Yuan-Ping Han; Yih-Dar Nien; Warren L Garner
Journal:  J Biol Chem       Date:  2002-05-09       Impact factor: 5.157

9.  The role of complement in experimental bullous pemphigoid.

Authors:  Z Liu; G J Giudice; S J Swartz; J A Fairley; G O Till; J L Troy; L A Diaz
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

10.  Proteinase inhibitors and pemphigus vulgaris. An in vitro and in vivo study.

Authors:  H Dobrev; L Popova; D Vlashev
Journal:  Arch Dermatol Res       Date:  1996-10       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.